Global CAR T Cell Therapy Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026

  • ID: 4564653
  • Report
  • Region: Global
  • Acute Market Reports
1 of 4

FEATURED COMPANIES

  • Celgene Corporation.
  • Cellectis.
  • Eureka Therapeutics
  • Immune Therapeutics
  • Juno Therapeutics
  • Kite Pharma
  • MORE
CAR T Cell Therapy Market - Growth, Future Prospects, Competitive Analysis, 2017 - 2025, the global CAR T cell therapy market is expected to expand at a CAGR of 5.96 % from 2017 to 2025.

Market Insights
CAR T cell therapy is the most hot topic discussed among oncologist throughout the globe. The FDA approved CAR T cell therapy are Tisagenleucel (Kymriah), Axicabtagene ciloleucel (Yescarta) and Tocilizumab (Actemra). During the clinical trial studies few side effects have been encountered in patients put on CAR T cell therapy are cytokine release syndrome, b-cell aplasia and tumor lysis syndrome.

Currently CD19 antigens have been approved by USFDA for the treatment of relapsed b-cell acute lymphocytic leukemia. CD 22 and CD 30 antigens show promising result in preclinical trials for the treatment of non-Hodgkin’s lymphoma.

Recent approval of CD19 antigens as CAR T cell therapy for the treatment of b cell acute lymphocytic leukemia and increasing number of children suffering with acute lymphocytic leukemia is responsible for the dominance of ALL. Non-Hodgkin’s lymphoma and multiple myeloma are being diligently studied by pharmaceutical players owing to their rising prevalence and lack of efficacy utilizing chemotherapy.

Rising prevalence of relapsed acute lymphocytic leukemia and technological advancement in the screening of cancer drives the North America CAR T cells therapy market. Moreover the domicile of pharmaceutical companies pioneering in CAR T cell therapy. Increasing geriatric population suffering with leukemia and government initiatives to fight cancer will result in the positive growth of CAR T cell therapy in Asia Pacific.

The major pharmaceutical players actively engaged in the CAR T cell therapy market are Bellicum Pharmaceuticals, Inc., Immune Therapeutics, Celgene Corporation, Cellectis, Kite Pharma, Eureka Therapeutics, Juno Therapeutics, Sorrento Therapeutics and Novartis AG among others.

Key Market Movements:
  • Rising prevalence of patients suffering with relapsed b cell acute lymphocytic leukemia
  • Proactive role adopted by regulatory agencies for the expedited approval of CAR T cell therapy
  • Promising pipeline for CAR T cell therapy focusing on CD22, CD30 antigens for the treatment of non-Hodgkin’s lymphoma and acute myeloid leukemia respectively
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Celgene Corporation.
  • Cellectis.
  • Eureka Therapeutics
  • Immune Therapeutics
  • Juno Therapeutics
  • Kite Pharma
  • MORE
Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global CAR T Cell Therapy Market Portraiture
2.1.1. Global CAR T Cell Therapy Market, by Targeted Antigen, 2017 (US$ Mn)
2.1.2. Global CAR T Cell Therapy Market, by Application, 2017 (US$ Mn)
2.1.3. Global CAR T Cell Therapy Market, by Geography, 2017 (US$ Mn)

Chapter 3. CAR T Cell Therapy Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography
3.6. Top 3 Countries: Global CAR T Cell Therapy Market, 2016-2026 (US$ Mn)
3.7. Competitive Landscape : Global CAR T Cell Therapy Market, by Key Players, 2016-2026 (US$ Mn)

Chapter 4. Global CAR T Cell Therapy Market, by Targeted Antigen, 2016 – 2026 (US$ Mn)
4.1. Overview
4.2. CD 19
4.3. CD 20
4.4. CD 22
4.5. CD 30
4.6. CD 33
4.7. GD 2
4.8. HER 1
4.9. HER 2
4.10. MESO
4.11. EGFRVLL

Chapter 5. Global CAR T Cell Therapy Market, by Application, 2016 – 2026 (US$ Mn)
5.1. Overview
5.2. Acute Lymphocytic Leukemia
5.3. Chronic Lymphocytic Leukemia
5.4. Non-Hodgkin’s Lymphoma
5.5. Multiple Myeloma
5.6. Acute Myeloid Leukemia
5.7. Hepatocellular Carcinoma
5.8. Pancreatic Cancer
5.9. Colorectal Cancer
5.10. Others

Chapter 6. Global CAR T Cell Therapy Market, by Geography, 2016 – 2026 (US$ Mn)
6.1. Overview
6.2. North America CAR T Cell Therapy Market Analysis, 2016– 2026
6.3. Europe CAR T Cell Therapy Market Analysis, 2016 – 2026
6.4. Asia Pacific CAR T Cell Therapy Market Analysis, 2016 – 2026
6.5. Latin America CAR T Cell Therapy Market Analysis, 2016 – 2026
6.6. Middle East & Africa CAR T Cell Therapy Market Analysis, 2016 – 2026

Chapter 7. Company Profiles
7.1. Bellicum Pharmaceuticals, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Celgene Corporation.
7.3. Cellectis.
7.4. Eureka Therapeutics
7.5. Immune Therapeutics
7.6. Juno Therapeutics
7.7. Kite Pharma
7.8. Novartis AG
7.9. Sorrento Therapeutics

List of Figures
FIG. 1 CAR T Cell Therapy: Market Segmentation
FIG. 2 Global CAR T Cell Therapy Market Share, by Targeted Antigen, 2017 (US$ Mn)
FIG. 3 Global CAR T Cell Therapy Market Share, by Application, 2017 (US$ Mn)
FIG. 4 Global CAR T Cell Therapy Market Share, by Geography, 2017 (US$ Mn)
FIG. 5 Attractive Investment Proposition, by Geography
FIG. 6 Market Competition Landscape, by Key Players, 2017
FIG. 7 Global CD 19 CAR T Cell Therapy Market, 2016 – 2026 (US$ Mn)
FIG. 8 Global CD 20 CAR T Cell Therapy Market, 2016 – 2026 (US$ Mn)
FIG. 9 Global CD 22 CAR T Cell Therapy Market, 2016 – 2026 (US$ Mn)
FIG. 10 Global CD 30 CAR T Cell Therapy Market, 2016 – 2026 (US$ Mn)
FIG. 11 Global CD 33 CAR T Cell Therapy Market, 2016 – 2026 (US$ Mn)
FIG. 12 Global GD 2 CAR T Cell Therapy Market, 2016 – 2026 (US$ Mn)
FIG. 13 Global HER 1 CAR T Cell Therapy Market, 2016 – 2026 (US$ Mn)
FIG. 14 Global HER 2 CAR T Cell Therapy Market, 2016 – 2026 (US$ Mn)
FIG. 15 Global MESO CAR T Cell Therapy Market, 2016 – 2026 (US$ Mn)
FIG. 16 Global EGFRVLL CAR T Cell Therapy Market, 2016 – 2026 (US$ Mn)
FIG. 17 Global Acute Lymphocytic Leukemia Market for CAR T Cell Therapy, 2016 – 2026 (US$ Mn)
FIG. 18 Global Chronic Lymphocytic Leukemia for CAR T Cell Therapy, 2016 – 2026 (US$ Mn)
FIG. 19 Global Non-Hodgkin’s Lymphoma Market for CAR T Cell Therapy, 2016 – 2026 (US$ Mn)
FIG. 20 Global Multiple Myeloma Market for CAR T Cell Therapy, 2016 – 2026 (US$ Mn)
FIG. 21 Global Acute Myeloid Leukemia Market for CAR T Cell Therapy, 2016 – 2026 (US$ Mn)
FIG. 22 Global Hepatocellular Carcinoma Market for CAR T Cell Therapy, 2016 – 2026 (US$ Mn)
FIG. 23 Global Pancreatic Cancer Market for CAR T Cell Therapy, 2016 – 2026 (US$ Mn)
FIG. 24 Global Colorectal Cancer Market for CAR T Cell Therapy, 2016– 2026 (US$ Mn)
FIG. 25 Global Other Applications Market for CAR T Cell Therapy, 2016 – 2026 (US$ Mn)

List of Tables
TABLE 1 Global CAR T Cell Therapy Market Portraiture
TABLE 2 Global CAR T Cell Therapy Market, by Targeted Antigen, 2016 – 2026 (US$ Mn)
TABLE 3 Global CAR T Cell Therapy Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 4 Global CAR T Cell Therapy Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 5 North America CAR T Cell Therapy Market Analysis, 2016 – 2026 (US$ Mn)
TABLE 6 Europe CAR T Cell Therapy Market Analysis, 2016 – 2026 (US$ Mn)
TABLE 7 Asia Pacific CAR T Cell Therapy Market Analysis, 2016 – 2026 (US$ Mn)
TABLE 8 Latin America CAR T Cell Therapy Market Analysis, 2016 – 2026 (US$ Mn)
TABLE 9 Middle East and Africa CAR T Cell Therapy Market Analysis, 2016 – 2026 (US$ Mn)
TABLE 10 Bellicum Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 11 Celgene Corporation: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 12 Cellectis: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 13 Eureka Therapeutics: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 14 Immune Therapeutics: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 15 Juno Therapeutics: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 16 Kite Pharma: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 17 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 18 Sorrento Therapeutics: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Bellicum Pharmaceuticals, Inc.
  • Celgene Corporation.
  • Cellectis.
  • Eureka Therapeutics
  • Immune Therapeutics
  • Juno Therapeutics
  • Kite Pharma
  • Novartis AG
  • Sorrento Therapeutics
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll